Abstracts tagged "Disease-Modifying Antirheumatic Drugs (Dmards)"

Abstract Number: 1981 • ACR Convergence 2022
Rho-GTPase Expression Recruits CD14+ Cells to Joints in Rheumatoid Arthritis and Predicts Good Response to JAK-inhibitor Treatment
Eric Malmhäll-Bah¹, Karin Andersson², Nina Oparina², Sofia Töyrä Silfverswärd³, Malin Erlandsson² and Maria Bokarewa³, ¹Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ²Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Goteborg, Sweden, ³Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden
Background/Purpose: While examining arthritis development in GGTaseI-deficient mice, we found that hyperactive Rho-GTPases regulate the thymic egress of CD4+ T cells to the peripheral lymphoid…
Abstract Number: 2149 • ACR Convergence 2022
Cycling versus Swapping Strategies in Psoriatic Arthritis: Results from the Rheumatic Diseases Portuguese Register
Francisca Guimarães¹, Maria Pontes-Ferreira¹, Catarina Soares¹, Hugo Parente², Carolina Ochôa Matos³, Roberto Costa³, Daniela Oliveira⁴, Catarina Abreu⁵, Rafaela teixeira⁶, Sofia Ferreira Azevedo⁷, João Madruga-Dias⁸, Filipe Araújo⁹, Carla Campinho Ferreira¹⁰, Daniela Santos-Faria² and José Tavares-Costa², ¹Rheumatology department, Unidade Local de Saúde do Alto Minho, Ponte de Lima, Viana do Castelo, Portugal, ²Rheumatology department, Unidade Local de Saúde do Alto Minho, Ponte de Lima, Portugal, ³Rheumatology Department, Centro Hospitalar Universitário Lisboa Norte, Lisboa, Portugal, ⁴Rheumatology Department, Centro Hospitalar Universitário São João, Porto, Portugal, ⁵Rheumatology Department, Hospital Garcia de Orta, Lisboa, Portugal, ⁶Rheumatology department, Centro Hospitalar Tondela-Viseu, Viseu, Portugal, ⁷Rheumatology Department, Centro Hospitalar do Baixo Vouga, Aveiro, Portugal, ⁸Rheumatology Service, Centro Hospitalar Médio Tejo, Tomar, Portugal, ⁹Rheumatology and Osteoporosis Unit, Hospital de Sant´Ana, SCML, Lisboa, Portugal, ¹⁰Rheumatology Department, Hospital de Braga, Braga, Portugal
Background/Purpose: This study aimed to compare the effectiveness and safety of switching to a second tumour necrosis factor alfa inhibitor (TNFi) – "cycling group" -…
Abstract Number: 0136 • ACR Convergence 2022
Sarcoidosis Incidence After mTOR Inhibitor Treatment
Matthew Baker¹, Emese Vágó², Yuhan Liu¹, Rong Lu¹, Suzanne Tamang³, Erzsébet Horváth-Puhó² and Henrik Sørensen², ¹Stanford University, Stanford, CA, ²Aarhus University Hospital, Aarhus, Denmark, ³Stanford Center for Population Health Sciences, Redwood City, CA
Background/Purpose: Mechanistic target of rapamycin (mTOR) inhibitors are effective in animal models of granulomatous disease, but their benefit in patients with sarcoidosis is unknown. We…
Abstract Number: 0307 • ACR Convergence 2022
Reduction in Structural Damage Progression and Improvement in Clinical Response with Abatacept Treatment in Patients with ACPA+, Early RA: Results from a Post Hoc Analysis of the AVERT-2 Study by Baseline Erosion Scores
Chahin Pachai¹, Sean E Connolly², Yoshiya Tanaka³, Vivian Bykerk⁴, Tom Huizinga⁵, Gustavo Citera⁶, Clifton O. Bingham III⁷, Shuyan Du¹, Godehard Hoexter⁸, Roy Fleischmann⁹, Subhashis Banerjee¹ and Paul Emery¹⁰, ¹Bristol Myers Squibb, Princeton, NJ, ²Bristol-Myers Squibb, Morrisville, PA, ³University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan, ⁴Hospital for Special Surgery, New York, NY, ⁵Leiden University Medical Center, Leiden, Netherlands, ⁶Instituto de Rehabilitación Psicofísica (IREP), Buenos Aires, Argentina, ⁷Johns Hopkins University, Baltimore, MD, ⁸Bristol Myers Squibb GmbH & Co. KGaA, Munich, Germany, ⁹University of Texas Southwestern Medical Center and Metroplex Clinical Research Center, Dallas, TX, ¹⁰Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: Presence of structural damage is an important risk factor for further damage progression over time in RA. Inhibition of damage progression is a key…
Abstract Number: 0612 • ACR Convergence 2022
Peripheral Blood and Synovial Fluid Natural Killer (NK) and Natural Killer T (NKT) Cell Immunophenotypes in Active Rheumatoid Arthritis and Their Role as Biomarkers of Methotrexate Response
Siddharth Jain¹, Bidya Laishangtham¹, Aastha Khullar¹, Biman Saikia¹ and Varun Dhir², ¹Postgraduate Institute of Medical Education and Research, Chandigarh, India, ²PGIMER, CHD, INDIA, Chandigarh, India
Background/Purpose: It is still unclear whether Natural Killer (NK) and Natural Killer T (NKT) cells play a pathogenic or protective role in Rheumatoid Arthritis (RA).…
Abstract Number: 0801 • ACR Convergence 2022
Impact of Diagnosis and Treatment of Tropheryma Whipplei Infection in Patients with Pre-existing Chronic Inflammatory Rheumatic Diseases: Data from the National Tw-IRD Registry
Damien CAILLET PORTILLLO¹, Xavier Puéchal², Yannick Degboe¹, Marie Kostine³, Alexia Michaut⁴, Andre Ramon⁵, Daniel Wendling⁶, Nathalie Costedoat-Chalumeau⁷, Pascal Richette⁸, Hubert Marotte⁹, Justine VIX¹⁰, Jean Jacques Dubost¹¹, Sebastien Ottaviani¹², Gaël Mouterde¹³, Anne Grasland¹⁴, Aline Frazier-Mironer¹⁵, Vincent GERMAIN¹⁶, Fabienne COURY¹⁷, Anne Tournadre¹¹, Martin Soubrier¹⁸, Pauline Brevet¹⁹, Laurent Cavalie²⁰, Laurent Arnaud²¹, Christophe Richez²², Adeline Ruyssen-Witrand²³ and Arnaud Constantin²⁴, ¹Pierre-Paul Riquet University Hospital, Toulouse & Toulouse III University - Paul Sabatier, Rheumatology, Toulouse, France, ²National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, ³Pellegrin Hospital, University Hospital of Bordeaux, Rheumatology, Bordeaux, France, ⁴Hospital center, Loire Vendée Ocean, Rheumatology, La Roche-sur-Yon, France, La Roche-sur-Yon, France, ⁵University Hospital of DIJON, Rheumatology, Dijon, France, ⁶CHU, University Teaching Hospital, Besançon, France, ⁷Inserm DR Paris 5, Paris, France, ⁸Department of Rheumatology, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France, ⁹INSERM 1059, Saint-Etienne, France, ¹⁰University Hospital of poitiers, Rheumatology, Poitiers, France, Poitiers, France, ¹¹University Hospital of Clermont Ferrand, Rheumatology, Clermont-Ferrand, France, ¹²Hopital Bichat-Claude Bernard, Paris, France, ¹³Lapeyronie Hospital, Montpellier, France, ¹⁴Louis-Mourier Hospital, AP-HP, Colombes, Rheumatology, Colombes, France, ¹⁵APHP Hôpital Lariboisire, Paris, France, ¹⁶Pau Hospital, Rheumatology, Pau, France, Pau, France, ¹⁷Pierre-Bénite Hospital, University Hospital Lyon, Rheumatology, Lyon, France, ¹⁸Gabriel-Montpied Hospital, Clermont-Ferrand, France, ¹⁹University Hospital of Rouen, Rheumatology, Rouen, France., Le Havre, France, ²⁰Purpan Hospital, Federal Institute of Biology (IFB), University Hospital, Toulouse, Biology, Toulouse, France, ²¹Hautepierre Hospital, University Hospital of Strasbourg, Rheumatology, Strasbourg, France, ²²Université de Bordeaux, Bordeaux, France, ²³CHU de Toulouse, Toulouse, France, ²⁴Toulouse University Hospital, Toulouse, France
Background/Purpose: Tropheryma whipplei (Tw) infection is a rare condition, characterized by inflammatory joint symptoms in more than 75% of the cases, which can lead the…
Abstract Number: 0929 • ACR Convergence 2022
Severe Low-Dose Methotrexate Toxicity in Elderly Patients with Inflammatory Rheumatic Diseases
Cara Kumar¹, Kristine Herrmann¹ and Martin Aringer², ¹Division of Rheumatology, Department of Medicine III, University Medical Center and Faculty of Medicine TU Dresden, Dresden, Germany, ²University Medical Center and Faculty of Medicine TU Dresden, Dresden, Germany
Background/Purpose: While mostly remarkably safe, low dose methotrexate (MTX) occasionally causes life-threatening events. We analyzed all patients with rheumatic diseases and severe MTX toxicity between…
Abstract Number: 1229 • ACR Convergence 2022
Erosion Score and Erosive Joint Number Using Radiography: Clinical Implications in Patients with ACPA+ Early RA Treated with Abatacept
Chahin Pachai¹, Sean E Connolly², Yoshiya Tanaka³, Vivian Bykerk⁴, Tom Huizinga⁵, Gustavo Citera⁶, Clifton O. Bingham III⁷, Shuyan Du¹, Godehard Hoexter⁸, Paul Emery⁹, Subhashis Banerjee¹ and Roy Fleischmann¹⁰, ¹Bristol Myers Squibb, Princeton, NJ, ²Bristol-Myers Squibb, Morrisville, PA, ³University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan, ⁴Hospital for Special Surgery, New York, NY, ⁵Leiden University Medical Center, Leiden, Netherlands, ⁶Instituto de Rehabilitación Psicofísica (IREP), Buenos Aires, Argentina, ⁷Johns Hopkins University, Baltimore, MD, ⁸Bristol Myers Squibb GmbH & Co. KGaA, Munich, Germany, ⁹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ¹⁰University of Texas Southwestern Medical Center and Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: Inhibition of structural joint damage progression is a key outcome measure in RA clinical trials. This can be assessed by progression of joint erosion…
Abstract Number: 1607 • ACR Convergence 2022
Machine Learning Identifies Biomarker of Non-Response to Methotrexate in Rheumatoid Arthritis
Vincent Bouget¹, Julien Duquesne¹, Paul-Henry Cournède², Bruno Fautrel³, Francis Guillemin⁴, Pascal de Jong⁵, Judith Heutz⁶, Marloes Verstappen⁷, Annette van der Helm-van Mil⁸, Xavier Mariette⁹ and Samuel Bitoun¹⁰, ¹Scienta Lab, Paris, France, ²Paris-Saclay University - CentraleSupelec, Paris, France, ³Sorbonne University Paris, France and Pierre Louis Institute of Epidemiology and Public Health, Paris, France, Paris, France, ⁴Université de Lorraine, APEMAC, Vandoeuvre-les-nancy, France, ⁵ErasmusMC, Hendrik Ido Ambacht, Netherlands, ⁶Erasmus Medical Center, Rotterdam, Netherlands, ⁷Leiden University Medical Center, Leiden, Netherlands, ⁸Leiden University Medical Center, Erasmus Medical Center, Leiden, Netherlands, ⁹Paris-Saclay University, Rueil Malmaison, Ile-de-France, France, ¹⁰Paris-Saclay University, Paris, France
Background/Purpose: Methotrexate (MTX) is the first line treatment for rheumatoid arthritis (RA). Unfortunately, 30% to 40% of RA patients do not respond to MTX with…
Abstract Number: 1982 • ACR Convergence 2022
Pluripotency Marker PBX1 Predicts Treatment Effect in Rheumatoid Arthritis
Karin Andersson¹, Eric Malmhäll-Bah², Nina Oparina¹, Tao Weiyang³, Malin Erlandsson¹, Venkataragavan Chandrasekaran², Aridaman Pandit³, Sofia Töyrä Silfverswärd⁴, Maria Bokarewa⁴ and Rille pullerits⁴, ¹Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Goteborg, Sweden, ²Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ³Center for Translational Immunology, University Medical Center, Utrecht, Netherlands, ⁴Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden
Background/Purpose: Self-renewal ability, which is important for the adaptive immunity and adequate T cell function, is severely impaired in rheumatoid arthritis (RA). This leads to…
Abstract Number: 2150 • ACR Convergence 2022
Cycling vs Swapping Strategies with TNFi and IL-17i in Psoriatic Arthritis: An Observational Retrospective Monocentric Study
Federica Lumetti¹, Alarico Ariani², Camilla Coccolini³, Carlo Salvarani⁴ and Gilda Sandri⁴, ¹Rheumatology Unit, AUSL of Modena and Azienda Ospedaliero Universitaria of Modena, Modena, Italy, ²Department of Medicine, Unit of Internal Medicine and Rheumatology, Azienda Ospedaliero Universitaria of Parma, Parma, Emilia-Romagna, Italy, ³Università di Modena e Reggio Emilia, Modena, Italy, ⁴Rheumatology Unit, Azienda Ospedaliero Universitaria of Modena, Modena, Italy
Background/Purpose: The therapy of psoriatic arthritis (PsA) was amplified in the last years with the introduction of a large amount of new biologic molecules with…
Abstract Number: 0192 • ACR Convergence 2022
Upadacitinib versus Adalimumab on Routine Assessment of Patient Index Data 3 (RAPID3) in Patients with Psoriatic Arthritis
Laura Coates¹, Arthur Kavanaugh², Erin McDearmon-Blondell³, Arthur Mandelin⁴, Tianming Gao⁵ and William Tillett⁶, ¹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom, ²University of California San Diego, La Jolla, CA, ³AbbVie, Inc., Mettawa, IL, ⁴Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵AbbVie, Inc., North Chicago, IL, ⁶Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom
Background/Purpose: RAPID3 (Routine Assessment of Patient Index Data 3) is a disease activity index calculated from 3 patient-reported measures: physical function, pain, and patient global…
Abstract Number: 0308 • ACR Convergence 2022
Risankizumab (RZB) Demonstrates Long-Term Efficacy Across Subgroups in Patients with Active Psoriatic Arthritis (PsA): A Post Hoc, Integrated Analysis from the Phase 3 (KEEPsAKE 1 and KEEPsAKE 2) Studies
Joseph Merola¹, Kristina Callis-Duffin², Byron Padilla³, Cuiyong Yue⁴, Huzefa Photowala⁴, Blair Kaplan⁴ and Iain B McInnes⁵, ¹Harvard Medical School, Brigham and Women's Hospital, Boston, MA, ²University of Utah, Salt Lake City, UT, ³AbbVie, Inc., Waukegan, IL, ⁴AbbVie, Inc., North Chicago, IL, ⁵Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom
Background/Purpose: Risankizumab (RZB), a fully humanized IgG1 monoclonal antibody inhibitor of IL-23, is a therapeutic agent approved for the treatment of active psoriatic arthritis (PsA)…
Abstract Number: 0699 • ACR Convergence 2022
Effectiveness by Disease Severity in Patients with Psoriatic Arthritis Treated with Apremilast in the CorEvitas Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Alexis Ogdie¹, Jacqueline O'Brien², Wendi Malley², Elizabeth Kohl², Kate Orroth³, Yuri Klyachkin⁴, Myriam Cordey⁵ and Philip J Mease⁶, ¹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²CorEvitas, LLC, Waltham, MA, ³Amgen, Manhattan Beach, CA, ⁴Amgen, Lexington, KY, ⁵Amgen, Inc., Thousand Oaks, CA, ⁶Swedish Medical Center/Providence St. Joseph Health, Seattle, WA
Background/Purpose: Clinical trials of the efficacy and safety of apremilast have shown a significant therapeutic effect on disease activity across clinically diverse PsA patients. Given…
Abstract Number: 0810 • ACR Convergence 2022
Analysis of Factors Associated with Good Therapeutic Response to Immunosuppressive Drugs in Patients with Non-infectious Uveitis: A Survival Analysis
María Paula Álvarez Hernández¹, Alejandro Gómez Gómez², Lara Borrego Sanz³, Rosalía Méndez Fernández³, Pedro Arriola Villalobos³, Esperanza Pato Cour⁴, David Díaz Valle³ and Luis Rodriguez-Rodriguez⁴, ¹Hospital Clínico San Carlos, Madrid, Spain, ²Hospital Infanta Sofia, Rheumatology, San Sebastián de los Reyes, Madrid, Spain, ³Instituto de Investigación Sanitaria San Carlos, Ophthalmology, Madrid, Spain, ⁴Instituto de Investigación Sanitaria San Carlos, Rheumatology, Madrid, Spain
Background/Purpose: Non-infectious uveitis (NIUs) encompass a varied group of inflammatory diseases affecting the uvea and adjacent tissues, with evidence suggesting an immune-mediated cause. A correct…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].